Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript

Group 1 - The company has experienced record sequential volume growth for Signatera, indicating strong demand and interest in the product [1][2] - There has been a notable shift in physician mentality towards minimal residual disease (MRD) testing, with increased visibility and discussions at major conferences such as ASCO [1] - The company is positioned as the market leader in MRD testing, holding a significant majority of market share, which is contributing to its growth [2]